Prosecution Insights
Last updated: April 19, 2026
Application No. 17/995,390

METHOD FOR PREPARING ANIMAL TISSUE-DERIVED BIOMATERIAL, ANIMAL TISSUE-DERIVED BIOMATERIAL PREPARED THEREBY, AND 3D PRINTING METHOD USING SAME

Final Rejection §112
Filed
Oct 03, 2022
Examiner
NOBLE, MARCIA STEPHENS
Art Unit
1632
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
T&R Biofab Co. Ltd.
OA Round
2 (Final)
67%
Grant Probability
Favorable
3-4
OA Rounds
3y 2m
To Grant
99%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allow Rate
560 granted / 837 resolved
+6.9% vs TC avg
Strong +40% interview lift
Without
With
+40.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
51 currently pending
Career history
888
Total Applications
across all art units

Statute-Specific Performance

§101
6.1%
-33.9% vs TC avg
§103
22.4%
-17.6% vs TC avg
§102
20.1%
-19.9% vs TC avg
§112
33.9%
-6.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 837 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Withdrawn Objections/Rejections The objections to claims 1, 3, and 5 are withdrawn. The suggested corrections made to the claims by amended. The rejection of claims 1-10, as presented in the last office action, under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention, is withdrawn. The amendments to the claims do not actually clarify the preparing of a primary solution as previously discussed and further add issues of indefiniteness. As such, the rejection is being withdrawn and a new rejection that addresses the new indefiniteness issues introduced by amendment will put in place. The following new rejection is necessitated by the amendments to the claims: Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claims, as amended or originally presented, still are generally narrative and indefinite, failing to conform with current U.S. practice. They appear to be a literal translation into English from a foreign document and are replete with grammatical and idiomatic errors. Claim 1, as amended, recites, “preparing a primary solution through 0.1 to 5 kDA ultrafiltration of the concentrate obtained through the separation”. By amending the claim to specify “through 0.1 to 5 kDA ultrafiltration of the concentrate”, the amendments now require the filtering step to be two ultrafiltration steps and not just one that produced the concentrate and the filtrate as was the indefiniteness issues discussed in the last office action. However, this amendment also adds a new issue of indefiniteness. The “concentrate” produced by ultrafiltration is a solid component separated from the liquid filtrate. As such, the relationship of the 0.1 to 5 kDA ultrafiltration to the making of the primary solution is not apparent because it is not apparent how the concentrate prepared for filtration and it is not apparent how the primary solution is being prepared (i.e. is the primary solution the filtrate of the 2nd ultracentrifugation or a solubilized form of the concentrate that results from the second 0.1 to 5kDA filtration). As such, the metes and bound of the “preparing a primary solution” are not apparent. Claims 2-10 depend upon claim 1 and thus also comprise the indefinite subject matter of claim 1. No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARCIA STEPHENS NOBLE whose telephone number is (571)272-5545. The examiner can normally be reached M-F 9-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached at 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. MARCIA S. NOBLE Primary Examiner Art Unit 1632 /MARCIA S NOBLE/Primary Examiner, Art Unit 1632
Read full office action

Prosecution Timeline

Oct 03, 2022
Application Filed
Sep 13, 2025
Non-Final Rejection — §112
Dec 15, 2025
Response Filed
Mar 04, 2026
Final Rejection — §112
Apr 09, 2026
Interview Requested

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12584104
OVARIAN FOLLICLE CELLS AND CONSTRUCTS FOR FERTILITY TREATMENT AND HORMONE REPLACEMENT THERAPY
2y 5m to grant Granted Mar 24, 2026
Patent 12584904
Methods for monitoring physiological status of a body organ
2y 5m to grant Granted Mar 24, 2026
Patent 12584149
NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED KITS
2y 5m to grant Granted Mar 24, 2026
Patent 12559729
INDUCTION OF HEPATOCYTES BY STEM CELL DIFFERENTIATION WITH RNA
2y 5m to grant Granted Feb 24, 2026
Patent 12559772
METHODS AND PRODUCTS FOR TRANSFECTING CELLS
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
67%
Grant Probability
99%
With Interview (+40.3%)
3y 2m
Median Time to Grant
Moderate
PTA Risk
Based on 837 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month